Liver transplant diabetes study tests which drug better reduces fatty liver
NCT ID NCT05042505
First seen Mar 06, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study looked at 100 people with diabetes who had a liver transplant. It compared two diabetes drugs, dapagliflozin and sitagliptin, to see which one better reduces liver fat and improves body composition over 12 months. Participants continued their usual care, including immunosuppressants. The goal was to find safer and more effective ways to manage diabetes and prevent fatty liver after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Division Of Endocrinology & Diabetes, Medanta The Medicity
Gurgaon, Haryana, 122001, India
Conditions
Explore the condition pages connected to this study.